Volastra Therapeutics

Chromosomal instability (CIN) is present in 60–80% of all human cancers, with some tumors being almost universally unstable, including high-grade serous ovarian cancer. At Volastra, we’re developing new therapies for hard-to-treat cancers by leveraging #KIF18A inhibition to exploit CIN as a key vulnerability of these tumors. On Saturday at #ESMO2025, a special symposium will focus on chromosomal instability as a therapeutic vulnerability in cancer. Our co-founder and CSO, Dr. Samuel Bakhoum, will be among the speakers presenting his academic work. Also presenting will be Dr. Ecaterina Dumbrava of The University of Texas MD Anderson Cancer Center, one of the investigators leading our ongoing Phase I/II trial of VLS-1488, a novel, oral #KIF18A inhibitor. We’re excited to see the growing recognition of CIN as a powerful target in oncology and proud to be at the forefront of translating this biology into new medicines for patients.

We were proud to sponsor and participate in Together in TEAL on Long Island this past weekend, joining patients, families, and advocates in raising awareness and supporting those impacted by ovarian cancer. Organized by the National Ovarian Cancer Coalition, this event unites communities to fund critical research, education, and programming. Supporting events like Together in TEAL reflects our commitment to advancing new treatments for ovarian cancer and to partnering with the patient community every step of the way. Pictured: Volastra team members, joined by friends and family, at the Together in TEAL 2025 #NOCAM2025 #TogetherInTEAL #OvarianCancerAwareness #KnowOvarian

September marks National Ovarian Cancer Awareness Month—a time to unite and shine a light on ovarian cancer. Together, we can amplify voices, share stories, and spread awareness to help save lives and support those impacted by this disease. At Volastra, we are committed to advancing new treatments for patients with ovarian cancer through our two clinical-stage KIF18A inhibitors, with the goal of delivering meaningful impact for patients and their families. #NOCAM2025 #OvarianCancerAwareness #KnowOvarian

We’re pleased to share that our CEO, David Southwell, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. We look forward to discussing our clinical-stage #KIF18A inhibitors and our mission to develop novel cancer therapeutics. #Oncology #Biotech #CIN

Last week, the Volastra team came together for a fun afternoon at the Empire Hotel in NYC. Enjoying the sunshine, food, and drinks allowed us to connect, recharge, and celebrate all of our hard work from the first half of 2025! #Biotech #NYC #Volastra

Volastra Therapeutics is hiring a Clinical Research Associate (CRA) to join our clinical operations team and support the execution of our oncology clinical trials. This role will be involved across trial start-up, maintenance, and close-out activities, contributing to the day-to-day operations of our clinical programs. We’re looking for someone who is detail-oriented, proactive, and eager to grow within a collaborative, fast-paced biotech environment.   https://lnkd.in/eSCmBbaZ   #Hiring #ClinicalResearch #ClinicalTrials #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs

Meet Cayley Gehnrich, Volastra's HR & Operations Manager. With a strong background in startups, Cayley plays a key role in shaping Volastra’s collaborative culture and supporting our growing team. Read more about what makes working in biotech so energizing for her below. #CareerJourneys #VolastraCareers #Oncology

Congratulations to our partners at Tailor Bio on their recent publication, which establishes the utility of their proprietary chromosomal instability (CIN) signatures in predicting resistance to cancer chemotherapies.    This publication represents major step forward for their platform and we look forward to our continued collaboration applying Tailor’s CIN signatures to potentially expand the use of KIF18A inhibitors across a broader array of tumor types.   #NatureGenetics #TailorBio #PrecisionOncology #KIF18A #OvarianCancer #CancerResearch

A proud moment at #ASCO25: data from the dose escalation portion of our Phase I/II study for our novel #KIF18A inhibitor, VLS-1488, earned a spot at the podium during the Development Therapeutics – Molecular Targeted Agents and Tumor Biology session. This milestone reflects the momentum behind #KIF18A inhibition and the dedication of our team and partners to advancing treatments for hard-to-treat cancers. Learn more here: https://lnkd.in/e69URRsv

MD Anderson is sharing 120+ studies at #ASCO25. Five stand out for their potential to transform care for thyroid, colorectal, ovarian and rare blood cancers. From innovative therapies to novel drug combos, these findings could help shape the next generation of treatment. See what's in store. #EndCancer